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ABSTRACT
Objective: To compare clinical rating scales of blepharospasm severity with involuntary eye closures
measured automatically from patient videos with contemporary facial expression software.
Methods: We evaluated video recordings of a standardized clinical examination from 50 patients
with blepharospasm in the Dystonia Coalition’s Natural History and Biorepository study. Eye
closures were measured on a frame-by-frame basis with software known as the Computer
Expression Recognition Toolbox (CERT). The proportion of eye closure time was compared with
3 commonly used clinical rating scales: the Burke-Fahn-Marsden Dystonia Rating Scale, Global
Dystonia Rating Scale, and Jankovic Rating Scale.
Results: CERT was reliably able to find the face, and its eye closure measure was correlated with
all of the clinical severity ratings (Spearman r 5 0.56, 0.52, and 0.56 for the Burke-Fahn-
Marsden Dystonia Rating Scale, Global Dystonia Rating Scale, and Jankovic Rating Scale,
respectively, all p , 0.0001).
Conclusions: The results demonstrate that CERT has convergent validity with conventional clin-
ical rating scales and can be used with video recordings to measure blepharospasm symptom
severity automatically and objectively. Unlike EMG and kinematics, CERT requires only conven-
tional video recordings and can therefore be more easily adopted for use in the clinic.
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GLOSSARY
BFM 5 Burke-Fahn-Marsden Dystonia Rating Scale; CERT 5 Computer Expression Recognition Toolbox; CI 5 confidence
interval; GDRS 5 Global Dystonia Rating Scale; ICC 5 intraclass correlation; JRS 5 Jankovic Rating Scale; UCSD 5 Uni-
versity of California, San Diego; WUSM 5 Washington University School of Medicine.
Blepharospasm is characterized by loss of voluntary control over orbicularis oculi muscles, caus-
ing involuntary eyelid closure. It is one of the most common forms of isolated dystonia and can
cause functional blindness, significant social disability, and decreased quality of life. Periodic
botulinum neurotoxin injections provide some symptomatic relief, but the development of
more effective therapies1,2 requires sensitive and objective methods to rate symptom severity.3,4
Current rating scales such as the Burke-Fahn-Marsden Dystonia Rating Scale (BFM),5,6 the
Global Dystonia Rating Scale (GDRS),7 the Jankovic Rating Scale (JRS),8 and the recently
developed rating scale for blepharospasm9 are based on inherently subjective clinician evalua-
tion. This raises concerns about interrater reliability and necessitates a substantial effort to
evaluate the reliability of such rating scales. In contrast, common availability of inexpensive
digital video cameras enables objective video recording analysis with a rapidly growing suite of
contemporary artificial intelligence software. One such implementation is the Computer
Expression Recognition Toolbox (CERT).10–13 CERT combines algorithms from computer
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vision and machine learning. It automatically
finds the face and detects facial “action units” on
the basis of the facial action coding system,14
widely used for coding facial expressions in
behavioral sciences.15 In neurologically normal
individuals, CERT demonstrates state-of-the-art
performance, discriminating emotions in bench-
mark datasets16 consisting of .100 individuals
producing .500 sequences of expressions.11,17
We evaluated the clinical utility of CERT
for measuring blepharospasm severity through
2 objectives: to test convergent validity, i.e.,
whether CERT measures of involuntary eye
closure agree with clinical severity ratings, and
to determine the viability of CERT, i.e., the
proportion of video frames on which CERT
can automatically find the patient’s face.
METHODS Patients. We evaluated patients previously re-
cruited into the Dystonia Coalition’s multicenter Natural History
and Biorepository of Isolated Dystonia cross-sectional study. The
biorepository includes a centralized, web-based platform for
securely uploading, storing, and serving patient data, including
video recordings.18 The system meets Health Insurance
Portability and Accountability Act guidelines for security and
has been approved by the Human Research Protection Office
at the Washington University School of Medicine (WUSM).
The Human Research Protection Office at the University of
California, San Diego (UCSD) also approved access to the
patient data by the UCSD team, including the ability to
observe streamed videos (protocol 111255X). We identified 50
patients with isolated dystonia, including at least blepharospasm
with or without lower facial involvement, for subsequent analysis
with CERT. Most patients were treated with botulinum
toxin, with the last injection at least 2 months before the
examination. Our only inclusion criterion was that the GDRS
and BFM clinical severity ratings were conducted at the same visit
as the video recording (for patient characteristics, see the table).
Clinical examination and severity ratings. Patients under-
went a standardized clinical examination based in part on a proto-
col developed by the Dystonia Study Group,7 modified to
accommodate features of many types of dystonia as described
by Yan et al.,18 and recorded with digital video at 30 frames per
second. We extracted from the videos the part of the examination
protocol focusing on blepharospasm (part I, steps 1–4).18 The
participant is seated in a chair facing the video camera. Feet are
resting on the floor, and hands are resting in the lap. The camera
is zoomed in to capture the head and shoulders only: (1) at rest,
eyes open for 10 seconds; (2) at rest, eyes closed gently for 10
seconds; (3) at rest, after eyes are opened, for another 10 seconds;
and (4) forced eyelid closure 3 times, with the effect observed for
5 seconds after each closure.
One patient was excluded from further analysis because she
was noted on observation to not fully close her eyes during peri-
ods of instructed eye closure.
Patient videos were accompanied by clinical severity scores. In
this study, we specifically focused on blepharospasm severity rat-
ings and did not include “duration” factors because of the rela-
tively short observation periods. Site ratings, normally conducted
live by clinicians who were familiar with the patient’s history,
included the upper face item from the BFM5,6 and GDRS.7 Three
movement disorders experts (M.H., H.J., J.P.), blinded to the live
ratings, scored the videos using the BFM, GDRS, and JRS.8
Interrater agreement was evaluated with the intraclass correlation
(ICC), and then the 3 raters’ video scores were averaged on each
patient for each rating scale.
Computational video analysis with CERT. To mitigate
security risks associated with transferring files containing video re-
cordings of patient faces, we developed an iterative video prepro-
cessing procedure between the Dystonia Coalition Biorepository
team at WUSM and the primary analysis team at UCSD. First, at
WUSM, video files were cropped to include just the relevant part
of the recording and saved as a separate file that was also re-encoded
for streaming. Second, the UCSD team reviewed the streamed
videos to validate proper cropping. Third, the WUSM team
manually segmented the videos into 9 periods of the examination
protocol, 5 periods when the eyes should be open and 4 periods
of instructed eye closures, using open-source video annotation
software (Elan,19 Max Planck Institute for Psycholinguistics, The
Language Archive, Nijmegen, the Netherlands), saving as outputs
the time stamps of each segment boundary. The WUSM team also
ran the video file through CERT. Both the segment boundary time
stamps and CERT outputs, without video or patient-identifying
information, were sent to the UCSD team as ASCII files. Fourth,
the UCSD team reviewed the Elan output files against the streamed
videos to validate the segmenting process.
In this study, we used CERT version 4.4.5, previously avail-
able from UCSD for academic use and now available as FACET
commercial software from iMotions.com (see the CERT process-
ing pipeline depicted in figure 1). Faces were automatically
located in each video frame by searching for standard facial land-
marks such as eyes, nose, and mouth using previously published
computer vision methods.17,20 We set an a priori criterion of 80%
to be the minimum proportion of face-found frames for reason-
able assessment of the patient’s eye closure features. The raw
output of CERT consisted of a continuous-valued measure of
eye closure for each video frame. Because of the nature of the
machine learning classifier from which it was derived, it was
dimensionless and relative, with more negative values associated
with open eyes and more positive with closed eyes. Downstream
analysis with the CERT raw measure of eye closure included only
the face-found frames and was conducted with MATLAB (The
Table Patient characteristics (n 5 49)
Demographics
Onset age, y 52 6 10 (30–71)
Sex, F/M 40/9
Disease duration, y 12 6 9 (1–41)
Severity ratings
BFM (live) 2.2 6 1.1 (0–4)
GDRS (live) 3.8 6 2.5 (0–10)
BFM (video) 2.2 6 0.9 (0–4)
GDRS (video) 3.7 6 1.8 (0–8)
JRS (video) 2.2 6 0.9 (0–4)
BFM 5 Burke-Fahn-Marsden Dystonia Rating Scale;
GDRS 5 Global Dystonia Rating Scale; JRS 5 Jankovic
Rating Scale.
Values expressed as mean 6 SD (range).
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MathWorks, Inc, Natick, MA). To determine the percentage of
time of eyes closed during the periods of instructed eye opening,
we needed a way to declare eyes open or closed on each video
frame, so we calculated an eye closure threshold for each patient.
The video examination protocol included substantial periods of
instructed eye closures and eye openings. For this protocol, the
distributions of the CERT raw eye closure measure over time
would be bimodal for neurologically normal individuals, in which
case choosing a threshold between eyes open and eyes closed
states would be trivial. In contrast, we hypothesized that the
distribution would not be bimodal for patients with blepharo-
spasm, so we first evaluated the distributions for bimodality using
the Sarle bimodality test (see appendix e-1 at Neurology.org). In
the event that .10% of the patients’ eye closure distributions
were not bimodal, we used a more conventional thresholding
method, similar to that used by Bologna et al.21 Specifically, we
calculated the mean of the means of the lowest 5% and highest
5% of samples. Using this per-patient eye closure threshold, we
calculated the percentage of time that each patient’s eyes were
closed when the patient was instructed to have them open, i.e.,
the number of video frames on which eyes are closed divided by
the total number of video frames from the concatenated eyes open
time segments.
Statistical analysis. Correlations were evaluated with the
Spearman rank correlation coefficient (r) with JMP (SAS Institute
Inc, Cary, NC) and characterized with the Cohen effect size con-
ventions.22 One-sided correlation comparisons weremade with Fisher
z transforms of the Spearman r values, parameterized for dependent
and overlapping groups (cocor,23 comparing correlations, 1.1–2,
http://comparingcorrelations.org). We used an a level of 0.05 to
determine significance and 95% confidence intervals (CIs).
RESULTS Clinical ratings. The demographics of our
patient cohort (table) were consistent with blepharo-
spasm epidemiology. Although their severity was, on
average, relatively mild (mean BFM 5 2.2 for both
live and video ratings and GDRS 5 3.8 and 3.7 for
live and video ratings, respectively), individual patient
severity ratings covered the full range of the severity
rating scales. Reliability among the 3 video raters was
assessed with the ICC, class 2, because all raters
rated all participants (Real Statistics Resource Pack
software, release 4.5, copyright 2013–2016, Charles
Zaiontz, www.real-statistics.com). There was
moderate agreement among the video raters on all 3
rating scales, consistent with prior studies using these
scales. Specifically, the ICCs (lower–upper CIs) were
0.58 (0.42–0.71) for the BFM, 0.62 (0.44–0.75) for
the GDRS, and 0.57 (0.39–0.72) for the JRS. The
live and video-based ratings were in general
agreement (figure 2) for both the BFM [Spearman
r(47) 5 0.61, p , 0.0001] and the GDRS
[Spearman r(47) 5 0.58, p , 0.0001].
CERT viability and convergent validity with clinical
scales. CERT was able to find the face in 100% of
the video frames for 46 patients and in 95%, 94%,
and 93% for the other 3 patients. Patients exhibited
a wide variety of bimodality in the distributions of
the CERT raw eye closure measure over all of the
Figure 1 Computer Expression Recognition Toolbox video processing pipeline
Video segments are analyzed on a frame-by-frame basis. Within the frame image, faces are located with the use of standard facial landmarks. After the face is
found, Gabor features are extracted and used in a high-dimensional support vectormachine (SVM) large-margin linear classifier, and the distance of the patient’s
metrics from the hyperplane determines the normalized eye closure magnitude, in arbitrary units (modified from Littlewort et al.,10 figure 2, with permission).
Figure 2 Clinical severity ratings: video vs live ratings
Clinical severity measures based on video vs live ratings for (A) Burke-Fahn-Marsden
Dystonia Rating Scale (BFM) and (B) Global Dystonia Rating Scale (GDRS), including linear
regression lines and 95% confidence intervals (shaded).
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video frames (figure 3). Some exhibited clearly
bimodal distributions (figure 3A), while others did
not (figure 3B). On the basis of the Sarle bimodality
test (see appendix e-1), a substantial portion (12 of
49, 24%) had distributions that were not bimodal
(figure 3C). Thus, we used the conventional method
for thresholding the eye closure output (see Methods).
This per-patient threshold was then used to determine
whether the eyes were closed on each video frame and the
percentage of frames during the instructed “eyes open”
segments used to calculate each patient’s CERT-based
metric: eye closure time (percent). The total duration of
the concatenated eyes open segments was 43 6 8
seconds (range 28–64 seconds). The CERT eye closure
time (percent) was correlated with all of the clinical rating
scales (figure 4), both for the live [BFM: Spearman
r(47) 5 0.46, p 5 0.0008; GDRS: Spearman
r(47) 5 0.30, p 5 0.035] and for the video-based
severity [BFM: Spearman r(47) 5 0.56, p , 0.0001;
GDRS: Spearman r(47) 5 0.52, p , 0.0001; JRS:
Spearman r(47) 5 0.56, p , 0.0001] ratings.
The correlations between the CERT eye closure
time (percent) and the severity ratings were higher
for the video-based than for the live severity ratings.
This difference (0.56 . 0.46) was not significant for
the BFM (based on Pearson and Filon z 5 0.953,
p 5 0.170 and Meng et al z 5 0.926, p 5 0.177,
difference CI 5 20.151 to 0.422). The difference
(0.52. 0.30) was, however, significant for the GDRS
(Pearson and Filon z 5 1.887, p 5 0.030 and Meng
et al z5 1.830, p5 0.034), although the difference CI
(20.019 to 0.553) is not consistent with an effect.
DISCUSSION We analyzed the CERT eye closure
measures to objectively compute the percent of time
that the patients’ eyes were closed when the patients
were instructed to open them. We found correlations
between this measure and all of the clinical severity
measures. Thus, the CERT eye closure measure ex-
hibits convergent validity with conventional clinician-
scored rating scales. This overarching result held
across all 3 clinical rating scales used (the BFM,
GDRS, and JRS), as well as the 2 modalities in
which they were administered (live and from video
observations).
The correlations between CERT and the clinical
severity ratings varied slightly, depending on whether
the ratings were live or based on video review. This is
expected, given the moderate but imperfect correlation
between the live and video-based rating modalities,
Figure 3 Eye closure thresholding
Frame-by-frame continuous-valued Computer Expression Recognition Toolbox measures of
eye closure during clinical examination, corresponding distributions over time, and bimodal-
ity of the distributions. Two sample patients: (A) one with and (B) one without a clear bimodal
distribution in eye closure. (C) Bimodality of patients’ eye closure distribution (sorted by
bimodality measure). Horizontal line represents threshold
abovewhich distribution is conventionally consideredbimodal
(Sarle b, see appendix e-1). BFM5 Burke-Fahn-Marsden Dys-
tonia Rating Scale; GDRS 5 Global Dystonia Rating Scale;
JRS 5 Jankovic Rating Scale. AU 5 arbitrary units.
Neurology 87 November 15, 2016 2149
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
a discrepancy that has been widely acknowledged24 but
not systematically investigated. There was a trend
toward the CERT eye closure measure correlating bet-
ter with video than live ratings, reaching significance for
some but not all statistical comparisons. CERT and the
video raters may detect eye closures that are missed by
a live rater who may not direct complete attention to
observing the patient when simultaneously recording
scores. Perhaps it is more important that the video
raters evaluate the same video that CERT analyzed,
which may enhance convergence.
CERT was robust with respect to variable head
movement and variable lighting conditions during
the video recording, reliably registering the face an
average of 99.6% of the video frames across all pa-
tients. The lowest percentage of face-found frames,
at 93%, far exceeded our a priori threshold of 80%
for retaining videos for further analysis. This is partic-
ularly encouraging for the relevance of CERT for pa-
tients with cranial dystonia with or without comorbid
cervical dystonia because about one-fourth of the pa-
tients in this study also had head tremor. It also sup-
ports the broader applicability of CERT for analyzing
video recordings from a conventional clinical setting
because no special efforts were made to optimize
lighting conditions in the present study.
The present study has a few noteworthy limita-
tions. First, severity is not uniformly distributed. In
the case of the GDRS, for example, the preponder-
ance of patients were rated 3 to 4, with relatively
few rated in the 1 to 2 and 8 to 10 ranges. Although
this likely represents the larger population of patients
diagnosed with blepharospasm, it diminishes our abil-
ity to test convergent validity among rating methods
at the low and high extremes of severity. Post hoc
review of the 2 notable outliers, patients with 80%
and 78% eye closure, suggests that these were legiti-
mate measures of severe blepharospasm and not
CERT processing artifacts. This emphasizes limita-
tions in the linearity of the clinical rating scales at
the high end. Second, the present study included
49 patients. A larger cohort may increase statistical
power and include more severe patients, depending
on the distribution in the population and any sam-
pling bias. Third, the video observation period may
be too brief, potentially providing insufficient dura-
tion of instructed eyes open periods to permit detec-
tion of low but still pathologic amounts of eye
closure. The floor effect apparent in the distributions
of the CERT eye closure measure (see figure 4), in
which several patients exhibited little if any eye closure
during the instructed eyes open periods, supports this
possibility. In this study, the cumulative duration of
instructed eyes open periods averaged 43 seconds,
whereas other studies used 120 seconds of video to
evaluate blink rate in blepharospasm.25,26 Nevertheless,
Figure 4 Convergent validity between Computer Expression Recognition Toolbox (CERT) and clinical severity ratings
Convergent validity between percent time of eye closure based on CERT and clinical severity ratings, separately for video (A–C) and live (D and E) clinical
rating modalities. Lines are linear regressions, and shaded regions show the 95% confidence intervals.
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the brief instructed eye open periods in the present
study were the same for CERT and for the video
reviewers, so both approaches had the same data on
which to base their analyses. Indeed, briefer observa-
tion periods, if sufficient to assay severity, could con-
tribute to clinical efficiency. All 3 of these limitations
could be addressed by CERT application to a larger
study incorporating a broader distribution of severity
and longer observation periods.
Our results further highlight concerns about the
reliability of inherently subjective methods for evalu-
ating blepharospasm severity and support the need for
more objective measures of motor symptoms in dys-
tonia.4,27 The 3 video reviewers, after conducting
a joint practice session to work toward consensus
on how to apply the rating scales immediately before
their independent ratings, exhibited only moderate
agreement (ICCz0.6) on the severity ratings across
these patients. The video raters also exhibited only
moderate correlation (Spearman r 5 0.58–0.61)
with the live raters. These interrater results are con-
sistent with those of previous reports using the BFM
and GDRS for blepharospasm.7 Objective measures
can mitigate the intrarater and interrater confounds
inherent in human assessments. Indeed, deterministic
algorithms such as the CERT eye closure measure
give intrarater and interrater variability of zero.
Regardless, no gold standard for comparison exists
for any of these measures. This is a concern for future
rating scale development, whether based on human
subjective ratings or automated objective ratings. We
expect that increased integration between clinical and
computational experts will provide stronger measures
than either approach in isolation.
As used in the present study, CERT provides
a partially automated means for assessing symptom
severity in blepharospasm. Further automation could
greatly alleviate the labor-intensive nature of human-
based video review, which can be tedious and error
prone and can require the valuable and limited
resource of blepharospasm experts. The core CERT
algorithm can already be used in a real-time mode.
Automating the input and output processes would
enable a real-time, end-to-end video processing capa-
bility. This would facilitate the translation of CERT
from research to routine clinical use. Although the
focus of the present study was severity, future studies
including a healthy control group could be conducted
to see whether the CERT measures could reliably
detect the presence of blepharospasm. Thus, future
development of CERT could include an Internet-
based service to provide objective screening and sever-
ity measures in near-real time while complying
with appropriate Health Insurance Portability and
Accountability Act and Institutional Review Board
requirements.
Using,2minutes of video recorded during a stan-
dard clinical examination, we have demonstrated that
CERT can objectively measure eye closure in bleph-
arospasm. No separate technology or procedure is
required during the examination, and the video can
be analyzed offline. Thus, a CERT-based objective
measure can supplement traditional subjective ratings
of blepharospasm severity with minimal additional
burden in the clinical setting.
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